WUHAN YZY BIOPHARMA CO., LTD.

武汉友芝友生物制药股份有限公司

02496.HK

Develops bispecific antibody therapies for cancer-associated complications, cancer, and age-related ophthalmologic diseases, with a pipeline of seven clinical-stage candidates led by M701 in Phase II trials for malignant ascites and malignant pleural effusion, in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Capacity and utilisation
• Losses and path to profitability
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Non-recurring gains and losses
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech